论文部分内容阅读
我国流行的肾综合征出血热(HFRS)病毒有汉滩病毒(Ⅰ型)和汉城病毒(Ⅱ型)二种血清型。因此,有必要研制能同时预防这二种型别的疫苗。目前,我国用于生产疫苗的三株HFRS病毒,对同型各毒株均表现较好的中和作用,但对异型病毒的交叉中和作用较差。经人体免疫三针后,对同型病毒的中和抗体阳转率可达90%,而对异型病毒的阳转率仅30%左右。过去我们在研制HFRS灭活疫苗时采用Ⅰ型毒株浙10作为毒种,为提高HFRS疫苗免疫效果,又筛选出Ⅱ型毒株浙37,将其用于HFRS双价灭活疫苗的研制。根据我国“临床观察用的HFRS试验性灭活疫苗的基本要求”中规定,用于HFRS疫苗的毒株应作纯毒试验。外源因子检查和中和试验是检查纯毒的重要方法。本文重点报告以细胞和动物二种方法用于检查浙37的纯毒试验。
China’s epidemic of hemorrhagic fever with renal syndrome (HFRS) virus Hantaan virus (Ⅰ) and Seoul virus (Ⅱ type) two serotypes. Therefore, there is a need to develop vaccines that will prevent both types of infections. At present, the three HFRS viruses used to produce the vaccine in our country all show good neutralization effect on the same type of strains, but have poor cross-neutralization effect on the heterotypic viruses. After three doses of human immunization, the positive rate of neutralizing antibody to the same virus can reach 90%, while the positive rate of heterotypic virus is only about 30%. In the past, when we developed HFRS inactivated vaccine type I strain Zhejiang 10 as a kind of virus, in order to improve the immune effect of HFRS vaccine, and screened type Ⅱ strain Zhe 37, HFRS bivalent inactivated vaccine. According to China’s “clinical observation of HFRS experimental inactivated vaccine basic requirements” stipulates that the strain used for HFRS vaccine should be tested for pure toxicity. Exogenous factor test and neutralization test is to check the important method of pure toxicity. This article focuses on the report of both cells and animals used to check Zhejiang 37 pure toxicity test.